-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dipraglurant in Blepharospasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dipraglurant in Blepharospasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dipraglurant in Blepharospasm Drug Details: Dipraglurant is under development for the treatment of...
-
Product Insights
Dystonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dystonia - Drugs In Development, 2023’, provides an overview of the Dystonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Blepharospasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Blepharospasm - Drugs In Development, 2023’, provides an overview of the Blepharospasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharospasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Spasmodic Torticollis (Cervical Dystonia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spasmodic Torticollis (Cervical Dystonia) - Drugs In Development, 2023’, provides an overview of the Spasmodic Torticollis (Cervical Dystonia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spasmodic Torticollis (Cervical Dystonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Cough – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Cough - Drugs In Development, 2023’, provides an overview of the Chronic Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Charcot-Marie-Tooth Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Charcot-Marie-Tooth Disease Type I A – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease Type I A - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease Type I A pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Charcot-Marie-Tooth Disease Type I – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease Type I - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...